Scott Weston

Cooley advised General Catalyst as lead investor in Charm Industrial’s $100 million Series B financing. Charm Industrial is a developer of carbon removal technology, using plants to capture carbon dioxide from the atmosphere, then converting biomass into a stable, carbon-rich liquid to be pumped deep underground. Harley Brown led the Cooley team advising General Catalyst.

Cooley advised Baylis Medical on its agreement to sell its cardiology business to Boston Scientific for an upfront payment of $1.75 billion. Michael McGrail, Michal Berkner, William Corcoran, Jacqueline Grise and Joshua Friedman led the Cooley team advising Baylis Medical.

Cooley advised the underwriters on DBV Technologies' concurrent $106.4 million initial public offering and $28.3 million secondary public offering on Euronext.

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company trades on the Nasdaq Global Market under the symbol "DBVT" and on Euronext under the symbol "DBV."

Citigroup Global Markets, Leerink Partners and Bryan, Garnier & Co. acted as joint global coordinators and joint book running managers of the global offering.

San Francisco – Cooley advised the underwriters on TriVascular Technologies' initial public offering. TriVascular is a medical device company that develops and commercializes innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. It now trades on the Nasdaq Global Stock Market under the symbol "TRIV."

JP Morgan Securities and Credit Suisse Securities (USA) acted as joint book-running managers for the offering. Canaccord Genuity and Stifel Nicolaus acted as co-managers.

Year-to-date in 2014, Cooley has advised on 47 completed public offerings, including 24 completed IPOs.

New York – Cooley advised the underwriters on Amedica's initial public offering. Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica now trades on the Nasdaq Capital Market under the symbol "AMDA."

JMP Securities acted as the sole book-running manager for the offering. Needham & Co. acted as co-manager for the offering.

In 2013, Cooley's capital markets practice had a record year, advising on 60 public offerings, including 23 IPOs that raised more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 24 completed public offerings, including 13 completed IPOs. Last year, Cooley attorneys also handled more than 120 M&A transactions, with an aggregate deal value of more than $12.4 billion.